Project Details
Projekt Print View

Identification and validation of H. pylori-associated gastric cancer biomarkers in Chinese and German populations

Subject Area Gastroenterology
Term from 2019 to 2023
Project identifier Deutsche Forschungsgemeinschaft (DFG) - Project number 410192478
 
Final Report Year 2025

Final Report Abstract

The project aimed to improve the early detection and biological understanding of gastric cancer (GC) by identifying novel molecular markers and validating them functionally in relevant models. The project combined genomic, epigenetic, proteomic, and serological approaches and leveraged a longstanding collaboration between the Technical University of Munich (TUM) and Peking University. Key achievements of the project include the development of two integrated, noninvasive biomarker models for gastric cancer screening and risk stratification. These models combine methylation markers, gene mutations, and *Helicobacter pylori* -specific antibody profiles derived from cell-free DNA and blood samples. Validated in a large, prospective, endoscopically monitored cohort from Linqu County, China —a high-incidence GC region—these models demonstrated high predictive power and are being considered for translational development. The corresponding findings have been published in the *International Journal of Cancer*. The project produced a broad portfolio of scientific outputs, including eight peer-reviewed publications across high-impact journals such as JAMA Network Open, Theranostics, Cell Reports Medicine, etc. The papers covered complementary biomarker strategies—ranging from proteomics and metabolomics to serological and genomic assays—as well as a systematic review of cell-free DNA for GC detection. The results from these diverse methodologies converge to support the feasibility of precision, noninvasive screening approaches for gastric cancer. In addition, the project generated a comprehensive systematic review of cell -free DNA as a diagnostic tool for GC as well as multiple original publications on proteomic and metabolomic signatures in plasma and urine, further enhancing the potential for noninvasive diagnostics. Functional studies on frequently mutated genes in GC, including RNF43 and ACVR2A, were conducted using CRISPR/Cas9-edited gastric cell lines and a newly developed transgenic mouse model, providing insight into their tumor-suppressive roles. Despite organizational challenges caused by the COVID-19 pandemic, the project fulfilled its scientific goals and generated a strong foundation for future translational studies and clinical validation of early GC detection tools.

Publications

 
 

Additional Information

Textvergrößerung und Kontrastanpassung